# James Tananbaum

> James Tananbaum is a Series C investor at Foresite Capital backing Biotechnology and Health Care. See 25 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [Foresite Capital](https://shizune.co/investors/profile/foresite-capital)
- Location: San Francisco, United States
- Total investments: 25
- Last investment: Jul 2024
- Lead investor: 56%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/in/jimtananbaum/
- Website: https://x.com/JTananbaum

James Tananbaum is a Series C investor at Foresite Capital in San Francisco focused on Biotechnology and Health Care. James Bruce Tananbaum is based out of San Francisco, California and is the Founder and Chief Executive Officer of Foresite Capital. James previously worked at Theravance Biopharma as a Co-Founder and Founding Chief Executive. James Bruce Tananbaum attended the Harvard.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 13 | 52% |
| Health Care | 9 | 36% |
| Life Science | 7 | 28% |
| Therapeutics | 4 | 16% |
| Medical | 3 | 12% |

18 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series C | 7 | 28% |
| Series B | 6 | 24% |
| Series E | 3 | 12% |
| Series A | 2 | 8% |
| Series D | 1 | 4% |

9 stages tracked in total.

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 13 | 52% |
| United Kingdom | 2 | 8% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Foresight Diagnostics | Foresight Diagnostics develops novel technology created to detect cancers earlier from a simple blood draw. | $33M | Series B | Jul 30, 2024 |  |
| Element Biosciences | Element Biosciences is a multi-disciplinary startup focused on innovating genetic analysis tools for the research and diagnostic markets. We are developing a modular and high-performing DNA sequencing platform that will deliver high quality data, workflow flexibility, and make next-generation sequencing technology more accessible. Our proprietaryapproach to improve the signal-to-noise ratio allows us to provide groundbreaking innovations in surface chemistry, instrumentation and biochemistry to drastically decrease the run cost and capital cost while delivering high sequencing data quality. | $277M | Series D | Jul 11, 2024 |  |
| Alumis | Alumis is a precision medicines company looking to eliminate the “all-comers” approach that is seen with today’s treatments for people with autoimmune disease. Even with the innovation of the last decade, many patients continue to cycle through the approved therapies while continuing to look for the right therapy to alleviate the impact of theirdisease without life-impacting side effects. Esker leverages a precision analytics platform, powered by Foresite Labs, coupled with a team of experts with deep experience in precision medicine drug development and immunology, in order to create medicines that change the lives of people with autoimmune disease. | $259M | Series C | Mar 06, 2024 |  |
| Genomics | Genomics plc aiming to lead the genomic transformation of healthcare, to develop and apply sophisticated analyses of massive integrated genomic and phenotypic datasets to learn about human biology and reveal the human wiring diagramThey will lead the way through this challenge, using their expertise and experience to unleash the potential ofgenomics and set the standards by which organisations and patients can benefit from genomic data. | $44.6M | Series C | Jan 08, 2024 |  |
| Foresight Diagnostics | Foresight Diagnostics develops novel technology created to detect cancers earlier from a simple blood draw. | $58.8M | Series B | Apr 27, 2023 |  |
| evonetix | evonetix is a new spin-out company that is currently incubating in the centre of the world-renowned Cambridge cluster of high-tech and life science organisations. We are seeking to develop and commercialise a new approach to the synthesis of DNA to facilitate the fast-emerging and exciting field of synthetic biology. By employing novel techniqueswe are able to advance DNA synthesis to levels never before seen. Our engineering team has decades of experience developing high integrity automated systems. Our high calibre team brings together expertise from across the scientific and engineering disciplines. | $24.1M | Series B | Feb 07, 2023 |  |
| DNAnexus | DNAnexus develops a cloud platform and global network designed for scientific collaboration and accelerated discovery. It provides security, scalability, and collaboration for enterprises and organizations that are pursuing genomic-based approaches to health in order to accelerate medical discovery. DNAnexus is supporting customers around the worldthat are tackling some of the most challenging and exciting opportunities in human health.The company was founded in 2009 and is based in Mountain View, California. | $200M | Series H | Mar 08, 2022 |  |
| ImmPACT Bio | ImmPACT Bio USA Inc. is a cell therapy company aiming to develop potent and selective engineered T-cells for the treatment of solid tumors. The Company's technology enables targeting loss-of-gene features of solid tumor cells, sparing normal, healthy tissues. | $139.9M | Series B | Jan 20, 2022 |  |
| XinThera | XinThera is a drug discovery company focused on building small molecule oncology and immunology pipeline. | $50M | Series B | Aug 04, 2021 |  |
| Element Biosciences | Element Biosciences is a multi-disciplinary startup focused on innovating genetic analysis tools for the research and diagnostic markets. We are developing a modular and high-performing DNA sequencing platform that will deliver high quality data, workflow flexibility, and make next-generation sequencing technology more accessible. Our proprietaryapproach to improve the signal-to-noise ratio allows us to provide groundbreaking innovations in surface chemistry, instrumentation and biochemistry to drastically decrease the run cost and capital cost while delivering high sequencing data quality. | $276M | Series C | Jun 29, 2021 |  |

10 of 25 investments shown.

## Co-investors
- [Google Ventures](https://shizune.co/investors/profile/google-ventures) — VC Fund, 5 deals together
- [Civilization Ventures](https://shizune.co/investors/profile/civilization-ventures) — VC Fund, 4 deals together
- [RA Capital Management](https://shizune.co/investors/profile/ra-capital-management) — VC Fund, 4 deals together
- [T. Rowe Price](https://shizune.co/investors/profile/t-rowe-price) — VC Fund, 4 deals together
- [ARCH Venture Partners](https://shizune.co/investors/profile/arch-venture-partners) — VC Fund, 3 deals together
- [CPP Investments](https://shizune.co/investors/profile/canada-pension-plan-investment-board) — VC Fund, 3 deals together

## About Foresite Capital

VC Fund · San Francisco, United States

Foresite Capital is a healthcare and life sciences investment firm. They take a data-driven approach to invest in startups that employ biology and big data to improve healthcare, such as 10x Genomics, Relay Therapeutics, Element Biosciences, and Inscripta.

5 contacts available at Foresite Capital.

| Name | Title | Profile |
| --- | --- | --- |
| Dorothy Margolskee | Managing Director | https://shizune.co/investors/profile/dorothy-margolskee |
| James Tananbaum | Founder and CEO | https://shizune.co/investors/profile/jim-tananbaum |
| Stephen C. Peterson | Partner | https://shizune.co/investors/profile/stephen-c-peterson |
| Dennis D. Ryan | CFO & Managing Director | https://shizune.co/investors/profile/dennis-d-ryan |
| Elizabeth Liz Canis | Senior Advisor | https://shizune.co/investors/profile/elizabeth-liz-canis |

## Similar investors

### Similar stage
- [Sequoia Capital](https://shizune.co/investors/profile/sequoia-capital) — VC Fund
- [New Enterprise Associates](https://shizune.co/investors/profile/new-enterprise-associates) — VC Fund
- [Bessemer Venture Partners](https://shizune.co/investors/profile/bessemer-venture-partners) — VC Fund

## FAQ

### What does James Tananbaum invest in?

James Tananbaum invests primarily in Biotechnology, Health Care and Life Science startups, most often at Series C and Series B stage. Most of the 25 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did James Tananbaum last invest?

The most recent investment recorded for James Tananbaum closed in Jul 2024. Shizune tracks 25 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co